Antiviral Drugs - Paraguay

Paraguay

The revenue forecast for the Antiviral Drugs market in Paraguay is expected to reach US$9.40m in 2024.
It is projected to exhibit a compound annual growth rate (CAGR 2024-2028) of 0.21%, leading to a market volume of US$9.48m by 2028.
When compared globally, United States is expected to generate the highest revenue, amounting to US$32,110.00m in 2024.
Paraguay's market for antiviral drugs is experiencing a surge in demand due to the increasing prevalence of viral infections in the country.

Key regions: France, Brazil, South Korea, India, China

Market

Region

Region comparison

Currency

Analyst Opinion

The demand for antiviral drugs in Paraguay has been increasing steadily over the years.

Customer preferences: Paraguayans are becoming more aware of the importance of antiviral drugs, especially with the rise of viral infections such as dengue fever and the recent COVID-19 pandemic. Customers are looking for effective treatments that can alleviate their symptoms and prevent the spread of the virus.

Trends in the market: The antiviral drugs market in Paraguay is expected to grow due to the increasing prevalence of viral infections. The demand for antiviral drugs has also been boosted by the government's efforts to improve the healthcare system and provide better access to medication. In addition, the market is driven by the increasing availability of generic antiviral drugs, which are more affordable than branded drugs.

Local special circumstances: Paraguay has a relatively small population compared to other countries in the region, which limits the size of the antiviral drugs market. However, the country's healthcare system is improving, and the government is investing in healthcare infrastructure to provide better access to medication. In addition, the country has a high incidence of dengue fever, which has led to an increased demand for antiviral drugs.

Underlying macroeconomic factors: Paraguay has a growing economy, and the healthcare sector is expected to benefit from this growth. The government is investing in healthcare infrastructure to improve access to medication and healthcare services. In addition, the country has a young population, which is expected to drive demand for healthcare services in the future. The increasing availability of generic antiviral drugs is also expected to boost the market.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.